Disruptive Behavior Disorder Treatment

Disruptive Behavior Disorder Treatment Market Outlook

The global Disruptive Behavior Disorder Treatment market is projected to reach approximately USD 7.6 billion by 2035, growing at a CAGR of about 8.2% from 2025 to 2035. This significant growth is attributed to the increasing prevalence of disruptive behavior disorders among children and adolescents, leading to a rising demand for effective treatment solutions. Furthermore, growing awareness regarding mental health and the importance of early intervention has propelled the need for various treatment options. Advances in research and development of more effective medications and therapy techniques to address the symptoms of disruptive behavior disorder are also contributing to market expansion. Moreover, the expansion of healthcare facilities and services aimed at addressing behavioral health issues has further fueled the demand for specialized treatment options.

Growth Factor of the Market

Several factors are driving the growth of the Disruptive Behavior Disorder Treatment market. Firstly, the increasing rate of diagnosis of disruptive behavior disorders such as Attention Deficit Hyperactivity Disorder (ADHD) and Oppositional Defiant Disorder (ODD) is leading to a greater demand for treatment options. Furthermore, rising investments in mental health research and increased funding from both government and private sectors are fostering the development of innovative treatment methods. Additionally, the growing recognition of the long-term impact of untreated behavioral disorders on individuals and society has led to an increased focus on prevention and management strategies by both healthcare providers and patients. The expansion of telehealth services, particularly following the COVID-19 pandemic, has improved access to mental health care, further contributing to the market's growth. Lastly, the growing trend of integrating behavioral health treatment with primary healthcare services is paving the way for more comprehensive care models, enhancing overall treatment efficacy.

Key Highlights of the Market

• Significant growth projected with a CAGR of 8.2% from 2025 to 2035.
• Increased awareness and diagnosis of behavioral disorders driving demand.
• Investment in innovative treatment solutions and research is on the rise.
• Expansion of telehealth services improving access to care.
• Integration of behavioral health into primary care systems gaining traction.

By Treatment Type

Medication:

Medication remains a cornerstone in the treatment of disruptive behavior disorders, offering symptomatic relief and supporting behavioral management. Stimulant medications, such as methylphenidate and amphetamines, are commonly prescribed for conditions like ADHD. These medications help improve focus and decrease impulsivity, significantly enhancing the quality of life for affected individuals. Non-stimulant medications, including atomoxetine and certain antidepressants, are also gaining traction as they provide effective alternatives, particularly for those who may not tolerate stimulant medications well. The pharmaceutical industry is continually innovating, developing new formulations and delivery methods to ensure better adherence and fewer side effects. The availability of more targeted therapies is expected to further bolster the medication segment of this market as healthcare providers seek to optimize treatment outcomes.

Therapy:

Therapeutic interventions are integral to the treatment of disruptive behavior disorders, focusing on changing negative behaviors and improving emotional regulation. Cognitive Behavioral Therapy (CBT) has proven effective by helping patients identify and alter harmful thought patterns. Additionally, Dialectical Behavior Therapy (DBT) equips individuals with coping strategies to manage intense emotions, making it particularly effective for adolescents. Family therapy involves parents and siblings in the treatment process, ensuring a supportive home environment conducive to behavior change. Furthermore, play therapy and art therapy are emerging as valuable tools, especially for younger children who may struggle to express their feelings verbally. The increasing acceptance and understanding of therapy as a viable treatment option continue to drive its demand within the market.

Parent Training:

Parent training programs are crucial in equipping caregivers with the tools and strategies necessary to manage the behaviors associated with disruptive behavior disorders effectively. These programs typically focus on teaching parents effective behavior management techniques, promoting positive reinforcement, and establishing healthy communication patterns. Research indicates that when parents are actively involved in their child's treatment, outcomes are often more favorable. Techniques such as positive parenting interventions not only help in managing the child's behavior but also foster a supportive environment that enhances the child’s emotional and psychological development. As awareness of the importance of parental involvement grows, the demand for parent training programs is expected to rise, contributing significantly to this segment.

School-Based Interventions:

School-based interventions play a vital role in addressing disruptive behavior disorders as they provide a structured environment where children spend a significant portion of their day. Programs implemented within schools focus on promoting positive behavior through social skills training, peer mediation, and individualized support plans. These interventions are often tailored to meet the specific needs of students and can include collaboration among teachers, counselors, and parents to create a comprehensive support network. Schools are increasingly recognizing the importance of mental health, leading to the incorporation of behavioral health professionals in educational settings. The rise in demand for effective school-based interventions highlights the essential role educational institutions play in addressing disruptive behavior disorders.

Multisystemic Therapy:

Multisystemic Therapy (MST) is an intensive, family-centered approach designed for adolescents with severe behavioral problems. This evidence-based treatment model addresses multiple aspects of a youth's environment, including family, school, and community, to facilitate comprehensive behavior change. MST therapists work closely with families, providing support and resources to promote positive interactions and reduce conflict. The holistic nature of MST sets it apart from traditional therapies, as it encompasses the various systems influencing a child’s behavior. The growing acknowledgment of the necessity for such multifaceted interventions has resulted in an increase in the adoption of MST, positioning it as a critical component in the Treatment market.

By Age Group

Children:

The children segment represents a significant portion of the Disruptive Behavior Disorder Treatment market, as many disorders manifest early in life. Conditions such as ADHD and ODD are increasingly being diagnosed in young children, leading to a pressing need for timely interventions. Effective treatment during these formative years is crucial, as early management can alter the trajectory of a child's development positively. Various treatment options are tailored specifically for children, including behavioral therapies and parent training programs designed to empower caregivers. The focus on preventative measures and early intervention strategies is expected to drive growth in this segment, as health professionals and parents alike recognize the importance of addressing behavioral issues promptly.

Adolescents:

The adolescent age group is another critical segment in the Disruptive Behavior Disorder Treatment market, as many individuals experience heightened emotional and social challenges during this developmental stage. Adolescents often exhibit more complex behavioral issues that require comprehensive treatment approaches. Therapeutic interventions, including individual therapy and family therapy, are particularly effective for this age group as they facilitate better communication and emotional expression. School-based interventions are also vital during adolescence, offering support in academic settings where behavioral disruptions may affect learning. The recognition of these unique needs is driving an increase in targeted treatment strategies for adolescents, facilitating continued growth within this market segment.

Adults:

Although disruptive behavior disorders are often associated with childhood and adolescence, there is a notable segment of adults who continue to experience these challenges. Adult treatment options typically focus on managing symptoms and addressing underlying issues, such as trauma or co-occurring mental health disorders. Therapies that promote emotional regulation and coping strategies are essential for adults seeking to manage disruptive behaviors effectively. Additionally, peer support groups and community-based interventions play a significant role in fostering social connections and accountability, which can aid in behavior modification. As awareness increases regarding the prevalence of disruptive behavior disorders in adults, the demand for tailored treatment options is also expected to rise, enhancing this segment's growth prospects.

By User

Hospitals:

Hospitals are primary providers of treatment for disruptive behavior disorders, offering a range of services from emergency interventions to comprehensive treatment programs. Inpatient care may be necessary in severe cases, where individuals receive intensive support and monitoring. Hospitals often collaborate with mental health professionals, including psychologists and psychiatrists, to develop individualized treatment plans. The infrastructure and resources available within hospitals enable them to conduct thorough assessments and implement evidence-based treatment modalities effectively. As healthcare systems increasingly recognize the importance of mental health care, hospitals are likely to expand their services and capabilities related to behavioral health, thereby driving growth in this segment.

Clinics:

Clinics represent a vital component of the Disruptive Behavior Disorder Treatment market, offering various outpatient services tailored to individual needs. These settings provide flexibility and accessibility for patients, allowing them to receive ongoing treatment and support. Clinics often focus on preventive care, aiming to intervene before behavioral issues escalate into more severe conditions. Therapeutic sessions and medication management can be provided in a community-based context, making treatment more accessible to diverse populations. The growing establishment of specialized clinics dedicated to mental health care is a trend that is likely to continue, further bolstering the market's expansion.

Rehabilitation Centers:

Rehabilitation centers play a crucial role in the treatment of disruptive behavior disorders, particularly for individuals with co-occurring substance use disorders. These centers provide structured environments that promote recovery and behavioral change through intensive therapy and support programs. Many rehabilitation centers incorporate family therapy and skills training into their treatment protocols, aiming to address the multifaceted nature of disruptive behavior. The holistic approach adopted by rehabilitation centers, which often encompasses physical, emotional, and social dimensions of care, is essential in fostering long-term recovery and behavior modification. As the societal stigma surrounding mental health decreases, the demand for services provided by rehabilitation centers is expected to grow.

Homecare Settings:

Homecare settings are becoming increasingly recognized as effective environments for treating disruptive behavior disorders, particularly for children and adolescents. Home-based interventions provide the advantage of familiar surroundings, which can alleviate anxiety and encourage participation in treatment. Homecare services often include behavioral management strategies, parent training, and therapy conducted by licensed professionals. The personalized nature of homecare allows for tailored interventions that are responsive to individual family dynamics and needs. With rising acceptance of homecare as a viable treatment option, this segment is poised for growth, reflecting the shifting preferences of patients and families seeking more adaptable care solutions.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies are a fundamental distribution channel for medications used in the treatment of disruptive behavior disorders. These pharmacies ensure that patients have access to essential medications that are often part of comprehensive treatment plans. Hospital pharmacies are equipped to manage specialized medication regimens and can provide critical counseling to patients receiving these prescriptions. Additionally, hospitals often have a coordinated care approach, where pharmacists work closely with healthcare providers to monitor treatment efficacy and manage potential side effects. The growing trend of personalized medicine further enhances the role of hospital pharmacies as they tailor medication strategies to individual patient needs, which is crucial in managing disruptive behavior disorders effectively.

Retail Pharmacies:

Retail pharmacies contribute significantly to the Disruptive Behavior Disorder Treatment market by providing accessible medication options for patients. These pharmacies offer a broad range of prescription and over-the-counter medications designed to assist in managing symptoms associated with disruptive behavior disorders. Retail pharmacies also serve as a convenient source of health information and medication counseling for patients and caregivers, ensuring they understand their treatment options. The rise of retail chains expanding their mental health services is an emerging trend, enhancing the role of these pharmacies in promoting mental health awareness. As patient preferences shift towards more accessible and community-based healthcare solutions, retail pharmacies are likely to play an increasingly important role in the distribution of medications for disruptive behavior disorders.

Online Pharmacies:

Online pharmacies have gained traction as a distribution channel, providing patients with convenient access to medications used in the treatment of disruptive behavior disorders. These platforms offer the advantage of privacy and discretion, which can be particularly appealing to individuals seeking mental health treatment. Online pharmacies often provide easy prescription refills and delivery options, ensuring that patients have uninterrupted access to their medications. Furthermore, many online pharmacies have integrated telehealth services, allowing patients to consult with healthcare providers remotely and receive necessary prescriptions without visiting a physical location. The growing acceptance of e-commerce in healthcare is expected to support the continued growth of online pharmacies within this market.

By Region

The Disruptive Behavior Disorder Treatment market is witnessing significant regional variations, with North America leading the sector due to a high prevalence of behavioral disorders and advanced healthcare infrastructure. In North America, the market is projected to reach approximately USD 3.1 billion by 2035, growing at a CAGR of 8.5%, driven by increased awareness, early diagnosis, and the integration of mental health services into primary care. The availability of a wide range of treatment options, including innovative therapies and medications, further enhances the market potential in this region. Additionally, the growing focus on mental health initiatives by governmental and non-governmental organizations is paving the way for improved access to treatment services across the continent.

In Europe, the market is also expanding, driven by rising awareness of mental health issues and improving access to treatment options. The European market is anticipated to reach around USD 2.1 billion by 2035, with a CAGR of 7.5% during the forecast period. Countries like Germany, the UK, and France are at the forefront of developing comprehensive mental health policies aimed at addressing disruptive behavior disorders. Furthermore, the collaboration between educational institutions and healthcare providers in implementing school-based interventions is instrumental in shaping the treatment landscape across Europe. As healthcare systems increasingly allocate resources to mental health care, the European market is likely to continue its upward trajectory.

Opportunities

As the Disruptive Behavior Disorder Treatment market continues to grow, several opportunities are emerging for stakeholders. The rising demand for personalized medicine is one such opportunity, as patients increasingly seek tailored treatment approaches that consider individual needs and circumstances. The development of novel therapeutic interventions, such as digital therapeutics and mobile health applications, presents a promising avenue for enhancing treatment accessibility and engagement. Furthermore, there is a growing trend towards integrating behavioral health into primary care settings, allowing for more comprehensive and holistic management of individuals with disruptive behavior disorders. This integration not only improves outcomes but also provides opportunities for collaboration among various healthcare providers, fostering a more connected healthcare ecosystem. Additionally, the expansion of telehealth services is creating new pathways for delivering care, particularly in underserved areas, ensuring that a broader population can access necessary treatment.

Moreover, increasing awareness and advocacy for mental health are driving initiatives aimed at reducing stigma and promoting early intervention for disruptive behavior disorders. Community-based programs focused on education, prevention, and support are gaining traction, offering significant opportunities for stakeholders in the market. By actively participating in these initiatives, organizations can enhance their visibility and strengthen their position within the industry. Additionally, partnerships with educational institutions to implement school-based interventions can pave the way for innovative treatment methodologies that address disruptive behavior at its root. As healthcare systems evolve, the demand for comprehensive, multidisciplinary treatment approaches is expected to rise, presenting further opportunities for growth and development within this market.

Threats

Despite the promising growth of the Disruptive Behavior Disorder Treatment market, several threats could hinder its progress. One significant challenge is the stigma surrounding mental health issues, which often leads to underdiagnosis and undertreatment of disruptive behavior disorders. Many individuals and families may be hesitant to seek help due to societal perceptions of mental health, resulting in delayed intervention and exacerbation of symptoms. Additionally, the complexity of managing disruptive behaviors, especially when they co-occur with other mental health disorders or substance use, complicates treatment efforts and may deter patients from pursuing necessary care. Furthermore, the rising costs associated with mental health services can act as a barrier to access, particularly for low-income populations. The lack of insurance coverage or reimbursement for certain treatment modalities can further exacerbate disparities in care, limiting access to necessary interventions.

Another potential threat is the rapid evolution of treatment methodologies and pharmaceuticals, which can lead to uncertainty and confusion among both patients and healthcare providers. As new therapies and medications enter the market, determining their effectiveness and appropriateness can be challenging. This constant change requires ongoing education and training for healthcare professionals to ensure they remain informed about the latest options and best practices. Additionally, the potential for over-reliance on pharmacological interventions without adequate therapeutic support may arise, raising concerns about treatment outcomes. As stakeholders navigate these threats, it is crucial to foster a culture of understanding and proactive engagement to mitigate their impact on the Disruptive Behavior Disorder Treatment market.

Competitor Outlook

• McNeil Consumer Healthcare
• Pfizer Inc.
• GlaxoSmithKline plc
• Novartis AG
• AstraZeneca plc
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Roche Holding AG
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Otsuka Pharmaceutical Co., Ltd.
• Horizon Therapeutics plc
• AbbVie Inc.
• Cephalon, Inc.
• Amgen Inc.

The competitive landscape of the Disruptive Behavior Disorder Treatment market is characterized by a mix of established pharmaceutical companies and emerging biopharmaceutical firms, all vying to capitalize on the growing demand for effective treatment options. Major players are heavily investing in research and development to innovate and refine treatment methodologies, focusing on both pharmacological and therapeutic solutions. Furthermore, collaborations between pharmaceutical companies and mental health organizations are becoming increasingly common, as these partnerships aim to enhance the understanding of disruptive behavior disorders and improve treatment accessibility. Companies are also emphasizing the importance of patient-centered care, developing programs and support systems that engage patients and families throughout the treatment process.

On the pharmaceutical front, companies such as Pfizer Inc. and Johnson & Johnson Services, Inc. are renowned for their extensive portfolios that include medications specifically designed for treating disruptive behavior disorders. Pfizer, for instance, offers a range of stimulant and non-stimulant options for ADHD, catering to diverse patient needs. Similarly, Johnson & Johnson has made significant contributions to the market with their innovative therapeutic approaches. These companies are also focusing on global expansion strategies to reach underserved populations in various regions, thereby enhancing their market presence and driving overall growth.

Emerging companies are also making their mark in the Disruptive Behavior Disorder Treatment market, often focusing on niche areas or innovative approaches to therapy. For example, companies specializing in digital therapeutics or mobile health applications are gaining traction as they provide new avenues for patient engagement and treatment delivery. As healthcare technology continues to evolve, these firms are poised to disrupt traditional treatment models and offer novel solutions that resonate with the modern patient demographic. Their agility in adapting to changing consumer preferences and technological advancements positions them favorably within the competitive landscape.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Cephalon, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 AstraZeneca plc
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 GlaxoSmithKline plc
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Horizon Therapeutics plc
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 McNeil Consumer Healthcare
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Otsuka Pharmaceutical Co., Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Johnson & Johnson Services, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Disruptive Behavior Disorder Treatment Market, By User
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Rehabilitation Centers
    • 6.1.4 Homecare Settings
  • 6.2 Disruptive Behavior Disorder Treatment Market, By Age Group
    • 6.2.1 Children
    • 6.2.2 Adolescents
    • 6.2.3 Adults
  • 6.3 Disruptive Behavior Disorder Treatment Market, By Treatment Type
    • 6.3.1 Medication
    • 6.3.2 Therapy
    • 6.3.3 Parent Training
    • 6.3.4 School-Based Interventions
    • 6.3.5 Multisystemic Therapy
  • 6.4 Disruptive Behavior Disorder Treatment Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Disruptive Behavior Disorder Treatment Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Disruptive Behavior Disorder Treatment market is categorized based on

By Treatment Type

• Medication
• Therapy
• Parent Training
• School-Based Interventions
• Multisystemic Therapy

By Age Group

• Children
• Adolescents
• Adults

By User

• Hospitals
• Clinics
• Rehabilitation Centers
• Homecare Settings

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• McNeil Consumer Healthcare
• Pfizer Inc.
• GlaxoSmithKline plc
• Novartis AG
• AstraZeneca plc
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Roche Holding AG
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Otsuka Pharmaceutical Co., Ltd.
• Horizon Therapeutics plc
• AbbVie Inc.
• Cephalon, Inc.
• Amgen Inc.